

## **GUIDANCE DOCUMENTS FOR REGULATORY SUBMISSIONS**

In an effort to help stakeholders get over the regulatory complexities involved in their interactions with the Health Authorities, ministries or regulators, Indian Society for Clinical Research (ISCR) has attempted to provide a gist of the various process documents that are required for submission in the various categories of trials and what needs to be done / submitted, in a simple, easy to understand format.

### **DISCLAIMER**

Whilst Indian Society for Clinical Research (ISCR) has taken every possible care in the compilation, preparation and presentation of the information published in the document, no liability whatsoever can be accepted for the contents or their accuracy. The contents of the document should not be construed as legal or regulatory advice. Readers are advised to seek specific legal and regulatory advice from a qualified professional person before undertaking any action in reliance on the contents of this publication. The materials in this document and site could include technical inaccuracies or typographical errors and are provided "as is" and without warranties of any kind either expressed or implied, to the fullest extent permissible pursuant to applicable law and regulation. ISCR disclaims all warranties of fitness for a particular purpose. ISCR does not warrant or make any representations regarding the use of or the results of the use of the materials in this site in terms of their correctness, accuracy, reliability, or otherwise. ISCR makes no commitment to update the materials on this site.

**For document see below**



## **Regulatory Requirements for Biotech products**

There seems to be no explicit regulatory guidelines currently available for filing a CTA with Biotech products.

This implies that the current regulations governing CTA's in general will hold true for Biotech products as well.

However on the website of the Department of Biotechnology ( Government of India ) a Draft 'National Biotechnology Development Strategy' is posted. This document can be accessed using the following URL. This being a draft strategy, it is basically only in the form of recommendations. Further one can visit page numbers 18, 34, 41 and 42 of this document to get an idea of how the future regulatory framework for clinical trials is likely to emerge.

<http://dbtindia.nic.in/biotechstrategy.htm>

Also existing 'REGULATORY MECHANISMS FOR GMO AND PRODUCTS THEREOF' can be accessed from the following URL

<http://dbtindia.nic.in/policy/polimain.html>

For marketing authorisation ( approval ) of Biotech products, the recommendations and proposed classification of Biotech products alongwith the proposed regulatory flowchart is given in 'Notification regarding adoption of the recommendations of the task force on r-pharma under the chairmanship of Dr R A Mashelkar, DG-CSIR with effect from 1. 4. 2006' This notification can be accessed by the following URL.

[http://envfor.nic.in:80/divisions/csurv/geac/rpharma\\_tf.pdf](http://envfor.nic.in:80/divisions/csurv/geac/rpharma_tf.pdf)